Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trifarotene in lamellar ichthyosis
NCT03738800Phase 2Terminated
- Sponsor
- Mayne Pharma
- Start
- May 2019
- Primary completion
- Sep 2021
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of CD5789 cream vehicle in lamellar ichthyosis (LI) (3 arms), sponsored by Mayne Pharma. Primary endpoint: Percentage of Subjects in Each Treatment Group Who Experienced Successful Resolution of LI at 90 days. Started May 2019; status: terminated.
02
Drugs
CD5789 cream vehicle
03
Conditions
lamellar ichthyosis (LI)
Beyond the preview
Go deeper on NCT03738800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738800.